HL7 FHIR Implementation Guide: Breast Cancer Data, Release 1 - US Realm (Draft for Comment 2)
This page is part of the Breast Cancer Data Logical Models and FHIR Profiles (v0.2.0: STU 1 Draft) based on FHIR R3. . For a full list of available versions, see the Directory of published versions 
<StructureDefinition xmlns="http://hl7.org/fhir"> <id value="oncology-ProgesteroneReceptorNuclearPositivity-model"/> <text> <status value="generated"/> <div xmlns="http://www.w3.org/1999/xhtml"> <p><b>BC ProgesteroneReceptorNuclearPositivity Logical Model</b></p> <p>The percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number.</p> </div> </text> <url value="http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-ProgesteroneReceptorNuclearPositivity-model"/> <identifier> <system value="http://hl7.org/fhir/us/breastcancer"/> <value value="oncology.ProgesteroneReceptorNuclearPositivity"/> </identifier> <version value="0.2.0"/> <name value="ProgesteroneReceptorNuclearPositivityModel"/> <title value="BC ProgesteroneReceptorNuclearPositivity Logical Model"/> <status value="draft"/> <date value="2018-08-17T00:00:00+10:00"/> <publisher value="The HL7 Cancer Interoperability Group sponsored by Clinical Interoperability Council Work Group (CIC)"/> <contact> <telecom> <system value="url"/> <value value="http://www.hl7.org/Special/committees/cic/index.cfm"/> </telecom> </contact> <description value="The percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number."/> <keyword> <system value="http://loinc.org"/> <code value="14230-7"/> <display value="Cells.progesterone receptor/100 cells in Tissue by Immune stain"/> </keyword> <kind value="logical"/> <abstract value="false"/> <type value="oncology-ProgesteroneReceptorNuclearPositivity-model"/> <baseDefinition value="http://hl7.org/fhir/StructureDefinition/Element"/> <derivation value="specialization"/> <snapshot> <element id="oncology-ProgesteroneReceptorNuclearPositivity-model"> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model"/> <definition value="The percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number."/> <min value="0"/> <max value="*"/> <base> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model"/> <min value="0"/> <max value="*"/> </base> <mustSupport value="false"/> <isModifier value="false"/> <isSummary value="false"/> </element> <element id="oncology-ProgesteroneReceptorNuclearPositivity-model.value"> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.value"/> <short value="Range representing the percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number."/> <definition value="Range representing the percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number."/> <min value="1"/> <max value="1"/> <base> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.value"/> <min value="1"/> <max value="1"/> </base> <type> <code value="http://hl7.org/fhir/us/breastcancer/StructureDefinition/shr-core-Range-model"/> </type> <mustSupport value="false"/> <isModifier value="false"/> <isSummary value="false"/> </element> <element id="oncology-ProgesteroneReceptorNuclearPositivity-model.topicCode"> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.topicCode"/> <short value="The concept representing the finding or action that is the topic of the statement."/> <definition value="The concept representing the finding or action that is the topic of the statement. For action topics, the TopicCode represents the action being described. For findings, the TopicCode represents the 'question' or property being investigated. For evaluation result findings, the TopicCode contains a concept for an observable entity, such as systolic blood pressure. For assertion findings, the TopicCode contains a code representing the condition, allergy, or other item being asserted. In all cases, the TopicCode describes the topic independent of the context of the action or the finding."/> <min value="0"/> <max value="1"/> <base> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.topicCode"/> <min value="0"/> <max value="1"/> </base> <type> <code value="Coding"/> </type> <mustSupport value="false"/> <isModifier value="false"/> <isSummary value="false"/> </element> <element id="oncology-ProgesteroneReceptorNuclearPositivity-model.exceptionValue"> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.exceptionValue"/> <short value="Reason that a value associated with a test or other finding is missing."/> <definition value="Reason that a value associated with a test or other finding is missing."/> <min value="0"/> <max value="1"/> <base> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.exceptionValue"/> <min value="0"/> <max value="1"/> </base> <type> <code value="Coding"/> </type> <mustSupport value="false"/> <isModifier value="false"/> <isSummary value="false"/> <binding> <strength value="extensible"/> <valueSetReference> <reference value="http://hl7.org/fhir/ValueSet/data-absent-reason"/> </valueSetReference> </binding> </element> <element id="oncology-ProgesteroneReceptorNuclearPositivity-model.interpretation"> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.interpretation"/> <code> <system value="http://ncimeta.nci.nih.gov"/> <code value="C0420833"/> </code> <short value="A clinical interpretation of a finding (applies to both assertions and observation)."/> <definition value="A clinical interpretation of a finding (applies to both assertions and observation)."/> <min value="0"/> <max value="1"/> <base> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.interpretation"/> <min value="0"/> <max value="1"/> </base> <type> <code value="Coding"/> </type> <mustSupport value="false"/> <isModifier value="false"/> <isSummary value="false"/> <binding> <strength value="extensible"/> <valueSetReference> <reference value="http://hl7.org/fhir/ValueSet/observation-interpretation"/> </valueSetReference> </binding> </element> <element id="oncology-ProgesteroneReceptorNuclearPositivity-model.referenceRange"> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.referenceRange"/> <code> <system value="http://ncimeta.nci.nih.gov"/> <code value="C0883335"/> </code> <short value="The usual or acceptable range for a test result."/> <definition value="The usual or acceptable range for a test result."/> <min value="0"/> <max value="0"/> <base> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.referenceRange"/> <min value="0"/> <max value="0"/> </base> <type> <code value="http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-topic-ReferenceRange-model"/> </type> <mustSupport value="false"/> <isModifier value="false"/> <isSummary value="false"/> </element> </snapshot> <differential> <element id="oncology-ProgesteroneReceptorNuclearPositivity-model"> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model"/> <definition value="The percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number."/> <min value="0"/> <max value="*"/> <base> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model"/> <min value="0"/> <max value="*"/> </base> <mustSupport value="false"/> <isModifier value="false"/> <isSummary value="false"/> </element> <element id="oncology-ProgesteroneReceptorNuclearPositivity-model.value"> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.value"/> <short value="Range representing the percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number."/> <definition value="Range representing the percentage of cells that test (stain) positive for the presence of progesterone receptors. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number. We are seeking feedback on whether nuclear positivity should be an exact percentage or a range of percentages. As currently defined, an exact nuclear positivity could be represented by a zero-width range, where the lower and upper bounds would be the same number."/> <min value="1"/> <max value="1"/> <base> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.value"/> <min value="1"/> <max value="1"/> </base> <type> <code value="http://hl7.org/fhir/us/breastcancer/StructureDefinition/shr-core-Range-model"/> </type> <mustSupport value="false"/> <isModifier value="false"/> <isSummary value="false"/> </element> <element id="oncology-ProgesteroneReceptorNuclearPositivity-model.topicCode"> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.topicCode"/> <short value="The concept representing the finding or action that is the topic of the statement."/> <definition value="The concept representing the finding or action that is the topic of the statement. For action topics, the TopicCode represents the action being described. For findings, the TopicCode represents the 'question' or property being investigated. For evaluation result findings, the TopicCode contains a concept for an observable entity, such as systolic blood pressure. For assertion findings, the TopicCode contains a code representing the condition, allergy, or other item being asserted. In all cases, the TopicCode describes the topic independent of the context of the action or the finding."/> <min value="0"/> <max value="1"/> <base> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.topicCode"/> <min value="0"/> <max value="1"/> </base> <type> <code value="Coding"/> </type> <mustSupport value="false"/> <isModifier value="false"/> <isSummary value="false"/> </element> <element id="oncology-ProgesteroneReceptorNuclearPositivity-model.exceptionValue"> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.exceptionValue"/> <short value="Reason that a value associated with a test or other finding is missing."/> <definition value="Reason that a value associated with a test or other finding is missing."/> <min value="0"/> <max value="1"/> <base> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.exceptionValue"/> <min value="0"/> <max value="1"/> </base> <type> <code value="Coding"/> </type> <mustSupport value="false"/> <isModifier value="false"/> <isSummary value="false"/> <binding> <strength value="extensible"/> <valueSetReference> <reference value="http://hl7.org/fhir/ValueSet/data-absent-reason"/> </valueSetReference> </binding> </element> <element id="oncology-ProgesteroneReceptorNuclearPositivity-model.interpretation"> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.interpretation"/> <code> <system value="http://ncimeta.nci.nih.gov"/> <code value="C0420833"/> </code> <short value="A clinical interpretation of a finding (applies to both assertions and observation)."/> <definition value="A clinical interpretation of a finding (applies to both assertions and observation)."/> <min value="0"/> <max value="1"/> <base> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.interpretation"/> <min value="0"/> <max value="1"/> </base> <type> <code value="Coding"/> </type> <mustSupport value="false"/> <isModifier value="false"/> <isSummary value="false"/> <binding> <strength value="extensible"/> <valueSetReference> <reference value="http://hl7.org/fhir/ValueSet/observation-interpretation"/> </valueSetReference> </binding> </element> <element id="oncology-ProgesteroneReceptorNuclearPositivity-model.referenceRange"> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.referenceRange"/> <code> <system value="http://ncimeta.nci.nih.gov"/> <code value="C0883335"/> </code> <short value="The usual or acceptable range for a test result."/> <definition value="The usual or acceptable range for a test result."/> <min value="0"/> <max value="0"/> <base> <path value="oncology-ProgesteroneReceptorNuclearPositivity-model.referenceRange"/> <min value="0"/> <max value="0"/> </base> <type> <code value="http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-topic-ReferenceRange-model"/> </type> <mustSupport value="false"/> <isModifier value="false"/> <isSummary value="false"/> </element> </differential> </StructureDefinition>